Compare Mesoblast Limited (MESO) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Synchrony Financial — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 13.7× Mesoblast Limited's market cap, and Synchrony Financial pays a 1.84% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Synchrony Financial for 28 Days on average.
| MESO | SYF | |
|---|---|---|
Market Cap | $1.75B | $23.99B |
Volume | 239,027 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $20.96 | $88.47 |
52-Week Low | $13.19 | $63.78 |
Typical Hold Time | 14 Days | 28 Days |
Enterprise Value | $1.83B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Synchrony Financial (SYF) trades at $71.93, down 0.32% today, with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 23.4% net income margin and 22.23% ROE, trading at attractive valuations (P/E 7.56x). Recent developments include partnerships with OpenAI and Vetspire to expand AI-driven commerce and veterinary financing capabilities, while Q3 2026 earnings are scheduled for October 20, 2026.
SYF presents a compelling value opportunity with strong earnings momentum and analyst consensus target of $87.58 (22% upside). However, technical weakness and increased investing outflows in 2026 create near-term headwinds. The stock offers shareholder returns through dividends and buybacks, but faces risks from consumer credit quality and competitive payment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
